The Effect of LY333531 on Protein in the Urine in Patients With Type 2 Diabetes
NCT ID: NCT00044148
Last Updated: 2017-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
2002-07-16
2004-04-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of LY3016859 in Participants With Diabetic Nephropathy
NCT01774981
A Study of LY2928057 in Hemodialysis Participants
NCT01991483
A Study in Participants With Diabetic Kidney Disease
NCT01113801
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
NCT01440257
Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria
NCT02410499
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY333531
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Greater than or equal to 30 years of age
* Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without language barrier.
Exclusion Criteria
* B/P greater than 150 systolic and greater than 90 diastolic
* Hemoglobin Alc greater than 11%
* Liver Function Tests 2 times upper limit of normal
* Poor medical or psychiatric risk.
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chromaderm, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
La Jolla, California, United States
Walnut Creek, California, United States
Jacksonville, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Lexington, Kentucky, United States
Baltimore, Maryland, United States
Waltham, Massachusetts, United States
Minneapolis, Minnesota, United States
St Louis, Missouri, United States
New York, New York, United States
Greenville, North Carolina, United States
Dallas, Texas, United States
Seattle, Washington, United States
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B7A-MC-MBDA
Identifier Type: -
Identifier Source: secondary_id
6249
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.